Endocrine Abstracts

Introduction: Pegvisomant is indicated for acromegaly. Doses >20 mg are not commercially available, although daily doses up to 30 mg are approved.Objectives: 1. To estimate the relative bioavailability (relBA) of single-dose pegvisomant s.c. administrations, one injection of 30 mg/ml (1×30) vs two injections of 15 mg/ml (2×15), and 2. To evaluate their pharmacokinetics (PK), safety and tolerability.Methods: This was a...